Arsenic and selenium toxicity and their interactive effects in humans

Environment International

Volumn 69, Issue , 2014, Pages 148-158

  Sun, Hong Jie ^a   Rathinasabapathi, Bala ^b   Wu, Bing ^a   Luo, Jun ^a   Pu, Li Ping ^c   Ma, Lena Q ^a,d  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

^c Suzhou Health College   (China)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antagonistic; Arsenic; Arsenite methyltransferase; Glutathione; Selenium; Synergistic

Indexed keywords

ARSENIC; PATHOLOGY; PEPTIDES; SELENIUM; TOXICITY;

ANTAGONISTIC; GLUTATHIONES; METHYLTRANSFERASES; REACTIVE OXYGEN SPECIES; S-ADENOSYLMETHIONINE; STRUCTURE AND ACTIVITIES; SYNERGISTIC; THIOREDOXIN REDUCTASE;

ARSENIC COMPOUNDS;

ARSENIC; REACTIVE OXYGEN METABOLITE; SELENIUM;

ARSENIC; ARSENITE; CHEMICAL POLLUTANT; CONCENTRATION (COMPOSITION); ENVIRONMENTAL RISK; EXCRETION; GENOTOXICITY; HEALTH IMPACT; HEALTH RISK; POLLUTION EXPOSURE; SELENIUM;

CELL DAMAGE; CELL MEDIATED CYTOTOXICITY; CHEMICAL INTERACTION; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME STRUCTURE; EPIDEMIOLOGICAL DATA; GENOTOXICITY; HEALTH HAZARD; HUMAN; METAL METABOLISM; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN METABOLISM; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANTAGONISTIC; ARSENIC; ARSENITE METHYLTRANSFERASE; GLUTATHIONE; SELENIUM; SYNERGISTIC;

ANIMALS; ARSENIC; CYTOTOXINS; DRUG INTERACTIONS; GLUTATHIONE; HUMANS; MACROMOLECULAR SUBSTANCES; METABOLIC NETWORKS AND PATHWAYS; METHYLTRANSFERASES; MODELS, CHEMICAL; MUTAGENS; RATS; SELENIUM;

EID: 84900875006     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2014.04.019     Document Type: Review

References (180)

1. Abhyankar L.N., Jones M.R., Guallar E., Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012, 120:494-500.
2. Abul-Hassan K.S., Lehnert B.E., Guant L., Walmsley R. Abnormal DNA repair in selenium-treated human cells. Mutat Res 2004, 565:45-51.
3. Akay C., Thomas C. Arsenic trioxide and paclitaxel induce apoptosis by different mechanism. Cell Cycle 2004, 3:322-332.
4. Amundson S.A., Myers T.G. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998, 17:3287-3300.
5. Andrew A.S., Karagas M.R., Hamilton J.W. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int J Cancer 2003, 104:263-268.
6. Andrew A.S., Burgess J.L., Meza M.M., Demidenko E., Waugh M.G., Hamilton J.W., et al. Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ Health Perspect 2006, 114:1193.
7. Apel K., Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 2004, 55:373-399.
8. Aro A., Alfthan G., Soimakallio S., Voutilainen E. Se concentrations in serum and angiographically defined coronary artery disease are uncorrelated. Clin Chem 1986, 32:911-912.
9. Bansal M.F., Mukhopadhyay T., Scott J., Cook R.G., Mukhopadhyay R., Medina D. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 1990, 11:2071-2073.
10. Bargonetti J., Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002, 14:86-91.
11. Becker D., Reul B., Ozcelikay A., Buchet J.P., Henquin J.C., Brichard S. Oral selenate improves glucose homeostasis and partly reverses abnormal expression of liver glycolytic and gluconeogenic enzymes in diabetic rats. Diabetologia 1996, 39:3-11.
12. Benbrahim-Tallaa L., Waterland R.A., Styblo M., Achanzar W.E., Webber M.M., Waalkes M.P. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 2005, 206:288-298.
13. +-coupled di-and tri-carboxylate/sulfate transporters. Mol Aspects Med 2013, 34:299-312.
14. Biswas S., Talukder G., Sharma A. Prevention of cytotoxic effects of arsenic by short-term dietary supplementation with selenium in mice in vivo. Mutat Res 1999, 441:155-160.
15. Biswas S., Talukder G., Sharma A. Chromosome damage induced by selenium salts in human peripheral lymphocytes. Toxicol In Vitro 2000, 14:405-408.
16. Blessing H., Kraus S., Heindl P., Bal W., Hartwig A. Interaction of selenium compounds with zinc finger proteins involved in DNA repair. Eur J Biochem 2004, 271:3190-3199.
17. Bleys J., Navas-Acien A., Guallar E. Selenium and diabetes: more bad news for supplements. Ann Intern Med 2007, 147:271-272.
18. Bleys J., Navas-Acien A., Guallar E. Serum selenium and diabetes in US adults. Diabetes Care 2007, 30:829-834.
19. Bleys J., Navas-Acien A., Laclaustra M., Pastor-Barriuso R., Menke A., Ordovas J., et al. Serum selenium and peripheral arterial disease: results from the national health and nutrition examination survey, 2003-2004. Am J Epidemiol 2009, 169:996-1003.
20. Bode A.M., Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 2002, 42:5-24.
21. Calvo A., Xiao N., Kang J., Best C.J., Leiva I., Emmert-Buck M.R., et al. Alterations in gene expression profiles during prostate cancer progression functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002, 62:5325-5335.
22. Centeno J.A., Mullick F.G., Martinez L., Page N.P., Gibb H., Longfellow D., et al. Pathology related to chronic arsenic exposure. Environ Health Perspect 2002, 110:883.
23. Chakraborti D., Mukherjee S.C., Pati S., Sengupta M.K., Rahman M.M., Chowdhury U.K., et al. Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger?. Environ Health Perspect 2003, 111:1194.
24. Challenger F. Biological methylation. Chem Rev 1945, 36:315-361.
25. Chen Q., Wang Z., Xiong Y., Zou X., Liu Z. Comparative study of p38 MAPK signal transduction pathway of peripheral blood mononuclear cells from patients with coal-combustion-type fluorosis with and without high hair selenium levels. Int J Hyg Environ Health 2010, 213:381-386.
26. Chiang E.C., Shen S., Kengeri S.S., Xu H., Combs G.F., Morris J.S., et al. Defining the optimal selenium dose for prostate cancer risk reduction: insights from the U-shaped relationship between selenium status, DNA damage, and apoptosis. Dose-Response 2010, 8:285-300.
27. Chiou H.Y., Huang W.I., Su C.L., Chang S.F., Hsu Y.H., Chen C.J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 1997, 28:1717-1723.
28. Chitta K.R., Figueroa J.A.L., Caruso J.A., Merino E.J. Selenium mediated arsenic toxicity modifies cytotoxicity, reactive oxygen species and phosphorylated proteins. Metallomics 2013, 5:673-685.
29. Chou W.C., Jie C., Kenedy A.A., Jones R.J., Trush M.A., Dang C.V. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A 2004, 101:4578-4583.
30. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin - a randomized controlled trial. JAMA 1996, 276:1957-1963.
31. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134.
32. Csanaky I., Gregus Z. Effect of selenite on the disposition of arsenate and arsenite in rats. Toxicology 2003, 186:33-50.
33. Devesa V., Del Razo L.M., Adair B., Drobná Z., Waters S.B., Hughes M.F., et al. Comprehensive analysis of arsenic metabolites by pH-specific hydride generation atomic absorption spectrometry. J Anal At Spectrom 2004, 19:1460-1467.
34. Douillet C., Currier J., Saunders J., Bodnar W.M., Matoušek T., Stýblo M. Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets. Toxicol Appl Pharmacol 2013, 267:11-15.
35. Duffield-Lillico A.J., Slate E.H., Reid M.E., Turnbull B.W., Wilkins P.A., Combs G.F., et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003, 95:1477-1481.
36. Eblin K., Bowen M., Cromey D., Bredfeldt T., Mash E., Lau S., et al. Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. Toxicol Appl Pharmacol 2006, 217:7-14.
37. El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res 2001, 475:123-139.
38. Fiala E.S., Staretz M.E., Pandya G.A., El-Bayoumy K., Hamilton S.R. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis 1998, 19:597-604.
39. Gailer J. Review: Reactive selenium metabolites as targets of toxic metals/metalloids in mammals: a molecular toxicological perspective. Appl Organomet Chem 2002, 16:701-707.
40. Gailer J. Arsenic-selenium and mercury-selenium bonds in biology. Coord Chem Rev 2007, 251:234-254.
41. Gailer J., Lindner W. On-column formation of arsenic-glutathione species detected by size-exclusion chromatography in conjunction with arsenic-specific detectors. J Chromatogr B 1998, 716:83-93.
42. Gailer J., George G.N., Pickering I.J., Prince R.C., Ringwald S.C., Pemberton J.E., et al. A metabolic link between arsenite and selenite: the seleno-bis (S-glutathionyl) arsinium ion. J Am Chem Soc 2000, 122:4637-4639.
43. Gailer J., George G.N., Harris H.H., Pickering I.J., Prince R.C., Somogyi A., et al. Synthesis, purification, and structural characterization of the dimethyldiselenoarsinate anion. Inorg Chem 2002, 41:5426-5432.
44. Gailer J., George G.N., Pickering I.J., Buttigieg G.A., Denton M.B., Glass R.S. Synthesis, X-ray absorption spectroscopy and purification of the seleno-bis (S -glutathionyl) arsinium anion from selenide, arsenite and glutathione. J Organomet Chem 2002, 650:108-113.
45. Gailer J., Buttigieg G., Denton M. Simultaneous arsenic-and selenium-specific detection of the dimethyldiselenoarsinate anion by high-performance liquid chromatography-inductively coupled plasma atomic emission spectrometry. Appl Organomet Chem 2003, 17:570-574.
46. Ganther H.E. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999, 20:1657-1666.
47. Gentry P.R., McDonald T.B., Sullivan D.E., Shipp A.M., Yager J.W., Clewell H.J. Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen 2010, 51:1-14.
48. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem J 2007, 401:1-11.
49. Hartwig A. Zinc finger proteins as potential targets for toxic metal ions: differential effects on structure and function. Antioxid Redox Signal 2001, 3:625-634.
50. Hatfield D.L., Yoo M.H., Carlson B.A., Gladyshev V.N. Selenoproteins that function in cancer prevention and promotion. BBA-Gen Subjects 2009, 1790:1541-1545.
51. Hayakawa T., Kobayashi Y., Cui X. Hirano S.A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol 2005, 79:183-191.
52. Hei T.K., Filipic M. Role of oxidative damage in the genotoxicity of arsenic. Free Radic Biol Med 2004, 37:574-581.
53. Ho E. Zinc deficiency, DNA damage and cancer risk. J Nutr Biochem 2004, 15:572-578.
54. Holmberg R.E., Ferm V.H. Interrelationships of selenium, cadmium, and arsenic in mammalian teratogenesis. Arch Environ Health 1969, 18:873-877.
55. Huang R., Lee T. Cellular uptake of trivalent arsenite and pentavalent arsenate in KB cells cultured in phosphate-free medium. Toxicol Appl Pharmacol 1996, 136:243-249.
56. Huang C., Ma W.Y., Li J., Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 1999, 59:3053-3058.
57. Huang Z., Pei Q., Sun G., Zhang S., Liang J., Gao Y., et al. Low selenium status affects arsenic metabolites in an arsenic exposed population with skin lesions. Clin Chim Acta 2008, 387:139-144.
58. Hudson T.S., Carlson B.A., Hoeneroff M.J., Young H.A., Sordillo L., Muller W.J., et al. Selenoproteins reduce susceptibility to DMBA-induced mammary carcinogenesis. Carcinogenesis 2012, 33:1225-1230.
59. Hughes M.F., Beck B.D., Chen Y., Lewis A.S., Thomas D.J. Arsenic exposure and toxicology: a historical perspective. Toxicol Sci 2011, 123:305-332.
60. Jiang X.H., Chun Y., Wong B., Yuen S.T., Jiang S.H., Cho C.H., et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of P53 and activation of caspase-3. Int J Cancer 2001, 91:173-179.
61. Kenyon E., Hughes M., Levander O. Influence of dietary selenium on the disposition of arsenate in the female B6C3F1 mouse. J Toxicol Environ Health 1997, 51:279.
62. Kim T.S., Jeong D.W., Yun B.Y., Kim I.Y. Dysfunction of rat liver mitochondria by selenite: induction of mitochondrial permeability transition through thiol-oxidation. Biochem Biophys Res Commun 2002, 294:1130-1137.
63. Kim T.S., Yun B.Y., Kim I.Y. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol 2003, 66:2301-2311.
64. Kim E.H., Sohn S., Kwon H.J., Kim S.U., Kim M.-J., Lee S.-J., et al. Sodium selenite induces superoxide-mediated mitochondrial damage and subsequent autophagic cell death in malignant glioma cells. Cancer Res 2007, 67:6314-6324.
65. Kircelli F., Akay C., Gazitt Y. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. Int J Oncol 2007, 30:993-1001.
66. Kitahara J., Seko Y., Imura N. Possible involvement of active oxygen species in selenite toxicity in isolated rat hepatocytes. Arch Toxicol 1993, 67:497-501.
67. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004, 44:239-267.
68. Kojima C., Ramirez D.C., Tokar E.J., Himeno S., Drobná Z., Stýblo M., et al. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst 2009, 101:1670-1681.
69. Kok F., De Bruijn A., Vermeeren R., Hofman A., Van Laar A., De Bruin M., et al. Serum selenium, vitamin antioxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. Am J Clin Nutr 1987, 45:462-468.
70. Kolachi N.F., Kazi T.G., Wadhwa S.K., Afridi H.I., Baig J.A., Khan S., et al. Evaluation of selenium in biological sample of arsenic exposed female skin lesions and skin cancer patients with related to non-exposed skin cancer patients. Sci Total Environ 2011, 409:3092-3097.
71. Kotsopoulos J., Chen Z., Vallis K.A., Poll A., Ghadirian P., Kennedy G., et al. Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes Control 2010, 21:679-687.
72. Kowalska E., Narod S.A., Huzarski T., Zajaczek S., Huzarska J., Gorski B., et al. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers 2005, 14:1302-1306.
73. Kraus R., Ganther H. Synergistic toxicity between arsenic and methylated selenium compounds. Biol Trace Elem Res 1989, 20:105-113.
74. Larabee J.L., Hocker J.R., Hanas J.S. Mechanisms of inhibition of zinc-finger transcription factors by selenium compounds ebselen and selenite. J Inorg Biochem 2009, 103:419-426.
75. Letavayová L., Vlčková V., Brozmanová J. Selenium: from cancer prevention to DNA damage. Toxicology 2006, 227:1-14.
76. Letavayová L., Vlasáková D., Spallholz J.E., Brozmanová J., Chovanec M. Toxicity and mutagenicity of selenium compounds in Saccharomyces cerevisiae. Mutat Res Fundam Mol Mech Mutagen 2008, 638:1-10.
77. Levander O.A. Metabolic interrelationships between arsenic and selenium. Environ Health Perspect 1977, 19:159.
78. Levander O., Argrett L. Effects of arsenic, mercury, thallium, and lead on selenium metabolism in rats. Toxicol Appl Pharmacol 1969, 14:308-314.
79. Lin S., Cullen W.R., Thomas D.J. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 1999, 12:924-930.
80. Liu Z., Shen J., Carbrey J.M., Mukhopadhyay R., Agre P., Rosen B.P. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci U S A 2002, 99:6053-6058.
81. Lu J., Jiang C., Kaeck M., Ganther H., Vadhanavikit S., Clement I., et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995, 50:213-219.
82. Manley S.A., George G.N., Pickering I.J., Glass R.S., Prenner E.J., Yamdagni R., et al. The seleno bis (S-glutathionyl) arsinium ion is assembled in erythrocyte lysate. Chem Res Toxicol 2006, 19:601-607.
83. Maritim A., Sanders R., Watkins R.J. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003, 17:24-38.
84. Mass M.J., Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997, 386:263-277.
85. Matschullat J. Arsenic in the geosphere - a review. Sci Total Environ 2000, 249:297-312.
86. McKenzie R.C., Arthur J.R., Beckett G.J. Selenium and the regulation of cell signaling, growth, and survival: molecular and mechanistic aspects. Antioxid Redox Signal 2002, 4:339-351.
87. Méplan C., Hughes D.J., Pardini B., Naccarati A., Soucek P., Vodickova L., et al. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010, 31:1074-1079.
88. Messarah M., Klibet F., Boumendjel A., Abdennour C., Bouzerna N., Boulakoud M.S., et al. Hepatoprotective role and antioxidant capacity of selenium on arsenic-induced liver injury in rats. Exp Toxicol Pathol 2012, 64:167-174.
89. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
90. Moxon A.L., DuBois K.P. The influence of arsenic and certain other elements on the Toxicity of seleniferous grains three figures. J Nutr 1939, 18:447-457.
91. Naranmandura H., Suzuki N., Suzuki K.T. Trivalent arsenicals are bound to proteins during reductive methylation. Chem Res Toxicol 2006, 19:1010-1018.
92. Navas-Acien A., Silbergeld E.K., Streeter R.A., Clark J.M., Burke T.A., Guallar E. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiologic evidence. Environ Health Perspect 2006, 114:641.
93. Nesnow S., Roop B.C., Lambert G., Kadiiska M., Mason R.P., Cullen W.R., et al. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 2002, 15:1627-1634.
94. Nickel A., Kottra G., Schmidt G., Danier J., Hofmann T., Daniel H. Characteristics of transport of selenoamino acids by epithelial amino acid transporters. Chem Biol Interact 2009, 177:234-241.
95. Ogra Y., Anan Y. Selenometabolomics: identification of selenometabolites and specification of their biological significance by complementary use of elemental and molecular mass spectrometry. J Anal At Spectrom 2009, 24:1477-1488.
96. Ohta Y., Suzuki K.T. Methylation and demethylation of intermediates selenide and methylselenol in the metabolism of selenium. Toxicol Appl Pharmacol 2008, 226:169-177.
97. Palmer I., Bonhorst C. Selenium Poisoning, Modification of Selenite Metabolism by Arsenite. J Agric Food Chem 1957, 5:928-930.
98. Papp L.V., Lu J., Holmgren A., Khanna K.K. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 2007, 9:775-806.
99. Park Y.-C., Whanger P.D. Toxicity, metabolism and absorption of selenite by isolated rat hepatocytes. Toxicology 1995, 100:151-162.
100. Park H.S., Park E., Kim M.S., Ahn K., Kim I.Y., Choi E.J. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem 2000, 275:2527-2531.
101. Paul D.S., Harmon A.W., Devesa V., Thomas D.J., Styblo M. Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ Health Perspect 2007, 734-742.
102. Pei Q., Ma N., Zhang J., Xu W., Li Y., Ma Z., et al. Oxidative DNA damage of peripheral blood polymorphonuclear leukocytes, selectively induced by chronic arsenic exposure, is associated with extent of arsenic-related skin lesions. Toxicol Appl Pharmacol 2012, 266:143-149.
103. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Vasken Aposhian H. Monomethylarsonous Acid ((MMA)(III)) Is More Toxic Than Arsenite in Chang Human Hepatocytes. Toxicol Appl Pharmacol 2000, 163:203-207.
104. Pilsner R.J., Hall M.N., Liu X., Ahsan H., Ilievski V., Slavkovich V., et al. Associations of plasma selenium with arsenic and genomic methylation of leukocyte DNA in Bangladesh. Environ Health Perspect 2011, 119:113-118.
105. Ramana C.V., Boldogh I., Izumi T., Mitra S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc Natl Acad Sci U S A 1998, 95:5061-5066.
106. Ramoutar R.R., Brumaghim J.L. Effects of inorganic selenium compounds on oxidative DNA damage. J Inorg Biochem 2007, 101:1028-1035.
107. Ravoori S., Srinivasan C., Pereg D., Robertson L.W., Ayotte P., Gupta R.C. Protective effects of selenium against DNA adduct formation in Inuit environmentally exposed to PCBs. Environ Int 2010, 36:980-986.
108. Rehman K., Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics 2012, 4:881-892.
109. Rodríguez-Lado L., Sun G., Berg M., Zhang Q., Xue H., Zheng Q., et al. Groundwater arsenic contamination throughout China. Science 2013, 341:866-868.
110. Rosen B.P., Liu Z. Transport pathways for arsenic and selenium: a minireview. Environ Int 2009, 35:512-515.
111. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003, 533:37-65.
112. Rossman T.G., Uddin A.N. Selenium prevents spontaneous and arsenite-induced mutagenesis. International Congress Series 2004, Elsevier.
113. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973, 179:588-590.
114. Ryan K.M., Phillips A.C., Vousden K.H. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001, 13:332-337.
115. Sah S., Smits J. Dietary selenium fortification: a potential solution to chronic arsenic toxicity. Toxicol Environ Chem 2012, 94:1453-1465.
116. Sah S., Vandenberg A., Smits J. Treating chronic arsenic toxicity with high selenium lentil diets. Toxicol Appl Pharmacol 2013, 272:256-262.
117. Schrauzer G.N. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr 2000, 130:1653-1656.
118. Sciandrello G., Caradonna F., Mauro M., Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004, 25:413-417.
119. Selenius M., Fernandes A.P., Brodin O., Björnstedt M., Rundlöf A.K. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: Effects on the thioredoxin system. Biochem Pharmacol 2008, 75:2092-2099.
120. Selvaraj V. Yeager-Armstead M, Murray E. Protective and antioxidant role of selenium on arsenic trioxide-induced oxidative stress and genotoxicity in the fish hepatoma cell line PLHC-1. Environ Toxicol Chem 2012, 31:2861-2869.
121. Selvaraj V., Tomblin J., Yeager Armistead M., Murray E. Selenium (sodium selenite) causes cytotoxicity and apoptotic mediated cell death in PLHC-1 fish cell line through DNA and mitochondrial membrane potential damage. Ecotoxicol Environ Saf 2013, 87:80-88.
122. Seo Y.R., Kelley M.R., Smith M.L. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 2002, 99:14548-14553.
123. Sharma V.K., Sohn M. Aquatic arsenic: toxicity, speciation, transformations, and remediation. Environ Int 2009, 35:743-759.
124. Shen H.M., Liu Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006, 40:928-939.
125. Shen L., Van Dyck K., Luten J., Deelstra H. Diffusibility of selenate, selenite, seleno-methionine, and seleno-cystine during simulated gastrointestinal digestion. Biol Trace Elem Res 1997, 58:55-63.
126. Shen H.M., Yang C.F., Ong C.N. Sodium selenite-induced oxidative stress and apoptosis in human hepatoma HepG2 cells. Int J Cancer 1999, 81:820-828.
127. Shen H., Yang C., Liu J., Ong C. Dual role of glutathione in selenite-induced oxidative stress and apoptosis in human hepatoma cells. Free Radic Biol Med 2000, 28:1115-1124.
128. Shen H.M., Yang C.F., Ding W.X., Liu J., Ong C.N. Superoxide radical-initiated apoptotic signalling pathway in selenite-treated HepG2 cells: mitochondria serve as the main target. Free Radic Biol Med 2001, 30:9-21.
129. Shi H., Hudson L.G., Ding W., Wang S., Cooper K.L., Liu S., et al. Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chem Res Toxicol 2004, 17:871-878.
130. Shi H., Shi X., Liu K.J. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 2004, 255:67-78.
131. Sies H., de Groot H. Role of reactive oxygen species in cell toxicity. Toxicol Lett 1992, 64-65:547-551.
132. Sinha D., Biswas J., Bishayee A. Nrf2-mediated redox signaling in arsenic carcinogenesis: a review. Arch Toxicol 2013, 87:383-396.
133. Song X., Geng Z., Li C., Hu X., Wang Z. Transition metal ions and selenite modulate the methylation of arsenite by the recombinant human arsenic (+3 oxidation state) methyltransferase (hAS3MT). J Inorg Biochem 2010, 104:541-550.
134. Spallholz J.E. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 1994, 17:45-64.
135. Spallholz J.E. Mallory Boylan L, Rhaman M, Environmental hypothesis: is poor dietary selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India?. Sci Total Environ 2004, 323:21-32.
136. Stapleton S. Selenium: an insulin mimetic. Cell Mol Life Sci 2000, 57:1874-1879.
137. Stewart M.S., Spallholz J.E., Neldner K.H., Pence B.C. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med 1999, 26:42-48.
138. Stranges S., Navas-Acien A., Rayman M.P., Guallar E. Selenium status and cardiometabolic health: state of the evidence. Nutr Metab Cardiovasc 2010, 20:754-760.
139. Stýblo M., Thomas D.J. In vitro inhibition of glutathione reductase by arsenotriglutathione. Biochem Pharmacol 1995, 49:971-977.
140. Styblo M., Thomas D.J. Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol Appl Pharmacol 2001, 172:52-61.
141. Styblo M., Delnomdedieu M., Thomas D.J. Mono-and dimethylation of arsenic in rat liver cytosol in vitro. Chem Biol Interact 1996, 99:147-164.
142. Suzuki K.T. Metabolomics of selenium: Se metabolites based on speciation studies. J Health Sci 2005, 51:107-114.
143. Suzuki Y.J., Forman H.J., Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997, 22:269-285.
144. Suzuki K.T., Kurasaki K., Suzuki N. Selenocysteine β-lyase and methylselenol demethylase in the metabolism of Se-methylated selenocompounds into selenide. BBA-Gen Subjects 2007, 1770:1053-1061.
145. Tapio S., Grosche B. Arsenic in the aetiology of cancer. Mutat Res 2006, 612:215-246.
146. Tinggi U. Essentiality and toxicity of selenium and its status in Australia: a review. Toxicol Lett 2003, 137:103-110.
147. Valdiglesias V., Pásaro E., Méndez J., Laffon B. In vitro evaluation of selenium genotoxic, cytotoxic, and protective effects: a review. Arch Toxicol 2010, 84:337-351.
148. Valko M., Rhodes C., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40.
149. Ventura J.-J., Cogswell P., Flavell R.A., Baldwin A.S., Davis R.J. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Gene Dev 2004, 18:2905-2915.
150. Villa-Bellosta R., Sorribas V. Role of rat sodium/phosphate cotransporters in the cell membrane transport of arsenate. Toxicol Appl Pharmacol 2008, 232:125-134.
151. Vinceti M., Maraldi T., Bergomi M., Malagoli C. Risk of chronic low-dose selenium overexposure in humans: insights from epidemiology and biochemistry. Rev Environ Health 2009, 24:231-248.
152. Vinceti M., Solovyev N., Mandrioli J., Crespi C., Bonvicini F., Arcolin E., et al. Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite. Neurotoxicology 2013, 38:25-32.
153. Vogelstein B., Lane D., Levine A. Surfing the p53 network. Nature 2000, 408:307-310.
154. Wallenberg M., Olm E., Hebert C., Bjornstedt M., Fernandes A. Selenium compounds are substrates for glutaredoxins: a novel pathway for selenium metabolism and a potential mechanism for selenium-mediated cytotoxicity. Biochem J 2010, 429:85-93.
155. Walton F.S., Waters S.B., Jolley S.L., LeCluyse E.L., Thomas D.J., Styblo M. Selenium compounds modulate the activity of recombinant rat AsIII-methyltransferase and the methylation of arsenite by rat and human hepatocytes. Chem Res Toxicol 2003, 16:261-265.
156. Wang T., Hsu T., Chung C., Wang A.S., Bau D., Jan K. Arsenite induces oxidative DNA adducts and DNA-protein cross-links in mammalian cells. Free Radic Biol Med 2001, 31:321-330.
157. Wang L., Bonorden M.J., Li G.-x., Lee H.-J., Hu H., Zhang Y., et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res 2009, 2:484-495.
158. Wang L., Kou M., Weng C., Hu L., Wang Y., Wu M. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-κB, and MAPK pathways. Arch Toxicol 2012, 86:879-896.
159. Waters S.B., Devesa V., Del Razo L.M., Styblo M., Thomas D.J. Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem Res Toxicol 2004, 17:404-409.
160. Waters D.J., Shen S., Glickman L.T., Cooley D.M., Bostwick D.G., Qian J., et al. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis 2005, 26:1256-1262.
161. 2 induces apoptosis with down-regulation of Bcl-2 and up-regulation of P53 expression in both immortal human hepatic cell line and hepatoma cell line. Mutat Res 2001, 490:113-121.
162. Wei M., Wanibuchi H., Morimura K., Iwai S., Yoshida K., Endo G., et al. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 2002, 23:1387-1397.
163. Weiller M., Latta M., Kresse M., Lucas R., Wendel A. Toxicity of nutritionally available selenium compounds in primary and transformed hepatocytes. Toxicology 2004, 201:21-30.
164. Whanger P. Selenium and its relationship to cancer: an update. Br J Nutr 2004, 91:11-28.
165. Xiang N., Zhao R., Song G., Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis 2008, 29:2175-2181.
166. Yamanaka K., Okada S. Induction of lung-specific DNA damage by metabolically methylated arsenics via the production of free radicals. Environ Health Perspect 1994, 102:37-39.
167. Yang C., Kuo M., Chen J., Chen Y. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999, 81:796.
168. Yih L.H., Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res 2000, 60:6346-6352.
169. Yoo M.H., Xu X.M., Carlson B.A., Patterson A.D., Gladyshev V.N., Hatfield D.L. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2007, 2:e1112.
170. Yoshida T., Yamauchi H., Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 2004, 198:243-252.
171. Yoshioka J., Schreiter E.R., Lee R.T. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006, 8:2143-2151.
172. Zachara B.A., Gromadzinska J., Palus J., Zbrog Z., Swiech R., Twardowska E., et al. The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: A pilot study. Biol Trace Elem Res 2011, 142:274-283.
173. 12 and glutathione does not require an enzyme. Toxicol Appl Pharmacol 1999, 154:287-291.
174. Zeng H., Combs G.F. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 2008, 19:1-7.
175. Zhang T., Schmitt M.T., Mumford J.L. Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 2003, 24:1811-1817.
176. Zhang H., Feng X., Chan H.-M., Larssen T. New insights into traditional health risk assessments of mercury exposure: implications of selenium. Environ Sci Technol 2014, 48:1206-1212.
177. Zhao C.Q., Young M.R., Diwan B.A., Coogan T.P., Waalkes M.P. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A 1997, 94:10907-10912.
178. Zhong C.X., Mass M.J. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol Lett 2001, 122:223-234.
179. Zhou N., Xiao H., Li T.K., Nur-E-Kamal A., Liu L.F. DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem 2003, 278:29532-29537.
180. Zhou X., Sun X., Cooper K.L., Wang F., Liu K.J., Hudson L.G. Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem 2011, 286:22855-22863.